FOLH1 and prostate cancer: It is also important to mention the possible toxicity of radiolabeled PSMA-targeted radiopharmaceuticals, as demonstrated in a pilot study by Khreish and collaborators, evaluating patients with prostate cancer in treatment with 177Lu-PSMA 617 and 225Ac-PSMA 617.